BR9813179A - Formulação de liberação prolongada - Google Patents

Formulação de liberação prolongada

Info

Publication number
BR9813179A
BR9813179A BR9813179-6A BR9813179A BR9813179A BR 9813179 A BR9813179 A BR 9813179A BR 9813179 A BR9813179 A BR 9813179A BR 9813179 A BR9813179 A BR 9813179A
Authority
BR
Brazil
Prior art keywords
extended release
release formulation
venlafaxine hydrochloride
formulation
provides
Prior art date
Application number
BR9813179-6A
Other languages
English (en)
Inventor
Deborah Marie Sherman
John Clifton Clark
John Ulrick Lamer
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25508423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9813179(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Prod filed Critical American Home Prod
Publication of BR9813179A publication Critical patent/BR9813179A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"FORMULAçãO DE LIBERAçãO PROLONGADA"<D>. Esta invenção refere-se a uma formulação de dosagem de liberação prolongada por 24 horas e a sua forma de dosagem unitária para cloridrato de venlafaxina, um antidepressivo, que proporciona um controle dos níveis plasmáticos sang³íneos melhor do que as formulações de comprimidos convencionais, que têm de ser administradas duas ou mais vezes ao dia, e também proporciona uma incidência de náusea e vómitos menor do que comprimidos convencionais. Em seu aspecto principal, esta invenção apresenta um núcleo aperfeiçoado de esferóides de liberação prolongada, composto por cloridrato de venlafaxina e celulose microcristalina, isto é, sem a adição de hidroxipropilmetil celulose.
BR9813179-6A 1997-11-05 1998-11-03 Formulação de liberação prolongada BR9813179A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96432897A 1997-11-05 1997-11-05
PCT/US1998/023338 WO1999022724A2 (en) 1997-11-05 1998-11-03 Extended release formulation containing venlafaxin

Publications (1)

Publication Number Publication Date
BR9813179A true BR9813179A (pt) 2000-08-22

Family

ID=25508423

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813179-6A BR9813179A (pt) 1997-11-05 1998-11-03 Formulação de liberação prolongada

Country Status (39)

Country Link
EP (1) EP1028718B1 (pt)
JP (1) JP2001521892A (pt)
KR (1) KR20010031797A (pt)
CN (1) CN1278165A (pt)
AR (1) AR014012A1 (pt)
AT (1) ATE237320T1 (pt)
AU (1) AU747978B2 (pt)
BG (1) BG104397A (pt)
BR (1) BR9813179A (pt)
CA (1) CA2305242A1 (pt)
CL (1) CL2004001705A1 (pt)
CO (1) CO5011060A1 (pt)
CZ (1) CZ20001659A3 (pt)
DE (1) DE69813602T2 (pt)
DK (1) DK1028718T3 (pt)
EA (1) EA200000487A1 (pt)
EE (1) EE04577B1 (pt)
ES (1) ES2196620T3 (pt)
GE (1) GEP20043198B (pt)
HK (1) HK1029056A1 (pt)
HR (1) HRP20000213B1 (pt)
HU (1) HU225238B1 (pt)
ID (1) ID26317A (pt)
IL (1) IL135457A0 (pt)
MA (1) MA24691A1 (pt)
NO (1) NO20002126L (pt)
NZ (1) NZ504460A (pt)
PA (1) PA8462501A1 (pt)
PE (1) PE128699A1 (pt)
PL (1) PL341141A1 (pt)
PT (1) PT1028718E (pt)
SK (1) SK6472000A3 (pt)
SV (1) SV1998000131A (pt)
TR (1) TR200001232T2 (pt)
TW (1) TW555568B (pt)
UA (1) UA77145C2 (pt)
UY (2) UY25234A1 (pt)
WO (1) WO1999022724A2 (pt)
ZA (1) ZA9810081B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2305606T3 (es) * 1999-04-06 2008-11-01 Sepracor Inc. Succinato de o-desmetilvenlafaxina.
AU782059B2 (en) * 1999-05-20 2005-06-30 Elan Pharma International Limited Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
CN1630631A (zh) * 2001-12-05 2005-06-22 惠氏公司 新的文拉法星盐酸盐多晶型物及其制备方法
AU2002247945A1 (en) * 2001-12-13 2003-06-23 Cadila Healthcare Limited Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof
WO2003055475A1 (en) * 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
AR039162A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Formulaciones de venlafaxina de liberacion extendida
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
US6696496B2 (en) 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
AU2003221535A1 (en) 2002-03-28 2003-10-13 Synthon B.V. Venlafaxine besylate
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
PT1502587E (pt) * 2003-07-30 2007-01-31 Pharmathen Sa Formulação de libertação prolongada para cloridrato de venlafaxina
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
RU2340331C2 (ru) 2004-02-04 2008-12-10 Алембик Лимитед Форма пролонгированного высвобождения венлафаксина гидрохлорида
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
WO2007112579A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Drug delivery composition
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
CN102772390B (zh) * 2012-08-16 2014-01-08 乐普药业股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
FR3080278B1 (fr) * 2018-04-11 2021-04-30 Ghs Patents Ltd Procede de fabrication d'un spheroide de cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
PA8462501A1 (es) 2000-05-24
ID26317A (id) 2000-12-14
PE128699A1 (es) 2000-01-06
HUP0004287A3 (en) 2002-05-28
AU747978B2 (en) 2002-05-30
UA77145C2 (en) 2006-11-15
ZA9810081B (en) 2000-05-04
NO20002126L (no) 2000-05-04
TR200001232T2 (tr) 2000-12-21
WO1999022724A2 (en) 1999-05-14
DE69813602T2 (de) 2003-11-06
NO20002126D0 (no) 2000-04-26
SK6472000A3 (en) 2000-11-07
CO5011060A1 (es) 2001-02-28
PL341141A1 (en) 2001-03-26
UY25234A1 (es) 2000-12-29
EE200000212A (et) 2001-04-16
EE04577B1 (et) 2006-02-15
WO1999022724A3 (en) 1999-07-22
HRP20000213A2 (en) 2000-12-31
GEP20043198B (en) 2004-03-25
HRP20000213B1 (en) 2004-04-30
EP1028718B1 (en) 2003-04-16
ES2196620T3 (es) 2003-12-16
CA2305242A1 (en) 1999-05-14
DK1028718T3 (da) 2003-07-28
HK1029056A1 (en) 2001-03-23
TW555568B (en) 2003-10-01
MA24691A1 (fr) 1999-07-01
AU1300399A (en) 1999-05-24
PT1028718E (pt) 2003-07-31
EP1028718A2 (en) 2000-08-23
DE69813602D1 (de) 2003-05-22
BG104397A (en) 2001-02-28
EA200000487A1 (ru) 2000-10-30
JP2001521892A (ja) 2001-11-13
IL135457A0 (en) 2001-05-20
SV1998000131A (es) 1999-11-18
NZ504460A (en) 2003-01-31
HU225238B1 (en) 2006-08-28
CN1278165A (zh) 2000-12-27
ATE237320T1 (de) 2003-05-15
CZ20001659A3 (cs) 2001-10-17
AR014012A1 (es) 2001-01-31
UY25692A1 (es) 2000-03-31
CL2004001705A1 (es) 2005-06-03
KR20010031797A (ko) 2001-04-16
HUP0004287A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
BR9813179A (pt) Formulação de liberação prolongada
JP3712420B2 (ja) ５―ｈｔアゴニストの処方物
KR970064599A (ko) 서방성 제형
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
EP1685839B8 (en) Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist
RU2005115855A (ru) Композиция трамадола продлонгированного высвобождением с 24-часовым действием
BR9815549A (pt) Composição farmacêutica para administração em dose única diária para alteração de lipìdios num indivìduo sem causar hepatotoxicidade induzida por drogas, miopatia ou rabdomiólise, comprimido revestido e método para administração de dita composição
HUP0301591A2 (hu) Szabályozott hatóanyag-leadású hidrokodon-készítmények
NO944565L (no) Preparat med regulert frigjörelse som inneholder et morfinsalt
DE69620606D1 (de) Feste oral anzuwendende arzeneiform
MX2007006212A (es) Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
CA2354057A1 (en) Sustained release tablet containing hydrocolloid and cellulose ether
BR9916361A (pt) Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
BR0016801A (pt) Preparação antidiabética para administração oral
TWI313598B (en) Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
PL404315A1 (pl) Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
EA200001201A2 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
BR9810337A (pt) Utilização de um antagonista especìfico dos receptores 5ht2 para a preparação de medicamentos úteis no tratamento da sìndrome de apnéia do sono
HUP9903410A2 (hu) Tolfenámsavat vagy gyógyszerészetileg elfogadható sóját tartalmazó, gyors hatóanyag-leadású tabletta
NO974956L (no) Terapeutisk sammensetning for artritis
ATE296632T1 (de) Molsidominhaltige oral anzuwendende verabreichungsform mit verzögerter wirkstoffabgabe
US5371082A (en) Treatment of anxiety disorders
ECSP982704A (es) Formula de liberacion prolongada
GEP20063804B (en) Once-a-day oxycodone formulations

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 36 DA LPI